The value of pharma schemes rose as investors shifted focus to drugmakers, considered defensive in uncertain times. As per data from Value Research the mid-cap category offered the highest return of 8.93%, followed by multi-caps which returned 7.88%.
Expect limited upside in near term, stick to stock-specific strategy; Vedanta, Motherson among top picks: CA Rudramurthy BV
Indian markets are struggling to maintain gains despite positive domestic news. Global factors and foreign selling are creating caution. Short-term traders are advised to reduce
December 10, 2025